Patient-derived organotypic tissue cultures as a platform to evaluate metabolic reprogramming in breast cancer patients

Five patient-derived organotypic cultures from patients with
treatment-naïve primary ER+/PR+/HER2- tumors while one came from a patient
with neoadjuvant therapy for locally metastatic ERlow/PR-/HER2- tumor.
They all exhibited tissue outgrowth in one month with some CA OTC
harboring isolatable organoids and fibroblasts. We interrogated
reprogrammed metabolism in CA versus paired NC OTC with dual
2H7-glucose/13C5,15N2-Gln tracers coupled with Stable Isotope-Resolved
Metabolomic analysis. The data are provided as Excel spreadsheets for each
patient. The entries comprise reduced data from FT-MS analyses in terms of
identified compounds, their ion intensities for each isotopologue,
injection volumes and derived normalized concentrations. These data can
therefore be reanalyzed as desired.